Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab

Lisa Rousseau (1) , Catherine Droitcourt (1, 2) , Nolwenn Ropars (1) , Bernard Lelong (3) , Clémence Saillard (1) , Alain Dupuy (1, 4)

1 Service de Dermatologie [Rennes] = Dermatology [Rennes]
2 CIC - Centre d'Investigation Clinique [Rennes]
3 Service de chirurgie thoracique cardiaque et vasculaire [Rennes] = Thoracic and Cardiovascular Surgery [Rennes]
4 IGDR - Institut de Génétique et Développement de Rennes

Anti-p200 pemphigoid is a rare autoimmune subepidermal blistering disease, first described in 1996.1 This disorder was initially considered as a more benign condition compared with bullous pemphigoid and epidermolysis bullosa acquisita, but in a recent series of patients, heterogeneous clinical presentations have been described, including cases with a more severe course than previously reported.2 We describe a case with a highly active disease in a heart transplant patient who experienced a dramatic and complete remission after 1 cycle of rituximab.

Keywords: heart transplant recipient; rituximab; anti-p200 pemphigoid; heart transplant recipient; rituximab

Domains: Life Sciences [q-bio]; Human health and pathology; Dermatology; Life Sciences [q-bio]; Immunology; Immunotherapy

Lisa Rousseau, Catherine Droitcourt, Nolwenn Ropars, Bernard Lelong, Clémence Saillard, et al.. Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab. JAAD Case reports, 2017, 3 (3), pp.175-177. ⟨10.1016/j.jdcr.2017.01.028⟩. ⟨hal-01518892⟩